HC Wainwright Forecasts Lower Earnings for Shattuck Labs

Shattuck Labs, Inc. (NASDAQ:STTK – Free Report) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Shattuck Labs in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.55) for the year, down from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.70) EPS.

Shattuck Labs (NASDAQ:STTK – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04).

STTK has been the subject of several other reports. JPMorgan Chase & Co. began coverage on shares of Shattuck Labs in a report on Friday, July 24th. They issued an “overweight” rating and a $10.00 price target for the company. TD Cowen upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush increased their price objective on shares of Shattuck Labs from $11.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, October 2nd. Raymond James Financial reissued a “strong-buy” rating on shares of Shattuck Labs in a report on Thursday. Finally, UBS Group initiated coverage on Shattuck Labs in a research note on Sunday, October 11th. They issued a “buy” rating and a $17.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.70.

Check Out Our Latest Stock Report on STTK

Shattuck Labs Price Performance

Shattuck Labs stock opened at $4.62 on Monday. Shattuck Labs has a 12 month low of $1.72 and a 12 month high of $8.33. The company has a fifty day moving average price of $6.00 and a two-hundred day moving average price of $6.02. The company has a market cap of $463.68 million, a PE ratio of -9.06 and a beta of 1.21.

Institutional Trading of Shattuck Labs

A number of large investors have recently modified their holdings of STTK. Fisher Asset Management LLC bought a new stake in Shattuck Labs in the 3rd quarter valued at about $575,000. Profund Advisors LLC acquired a new position in Shattuck Labs during the 3rd quarter valued at about $195,000. ProShare Advisors LLC bought a new position in Shattuck Labs in the 3rd quarter worth about $70,000. China Universal Asset Management Co. Ltd. grew its position in Shattuck Labs by 74.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 25,600 shares of the company’s stock worth $167,000 after purchasing an additional 10,959 shares during the last quarter. Finally, Pinnacle Associates Ltd. grew its position in Shattuck Labs by 12.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,099,779 shares of the company’s stock worth $14,320,000 after purchasing an additional 228,337 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

(Get Free Report)

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.

Read More

Earnings History and Estimates for Shattuck Labs (NASDAQ:STTK)

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.